Suppr超能文献

青蒿琥酯联合换血疗法治疗重症恶性疟:病例系列。

Exchange transfusion combined with artesunate (ET-AS) as a safe and effective therapy in severe P. falciparum malaria: a case series.

机构信息

Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, 272029, Shandong Province, China.

Institute of Blood and Marrow Transplantation, Jining Medical University, Jining, Shandong Province, China.

出版信息

BMC Infect Dis. 2024 Jun 19;24(1):603. doi: 10.1186/s12879-024-09381-2.

Abstract

BACKGROUND

the mortality associated with severe malaria due to Plasmodiun falciparum remains high despite improvements in malaria management. Case prensentation: this case series aims to describe the efficacy and safety of the exchange transfusion combined with artesunate (ET-AS) regimen in severe P. falciparum malaria. Eight patients diagnosed with severe P. falciparum malaria were included. All patients underwent ET using the COBE Spectra system. The aimed for a post-exchange hematocrit of 30%. Half the estimated blood volume was removed and replaced using fresh frozen plasma. The regimen was well-tolerated without complications. The parasite clearance time ranged from 1 ~ 5 days. Five patients with cerebral malaria exhibited full improved consciousness within 3 days, while patient2 with hemolysis improved on day 2. Liver function improved within 1 ~ 6 days, and patient 1 and patient 6 showed improvements renal function on days 18 and 19, respectively. The length of intensive care unit stay range from 2 ~ 10 days, and all patients treated with ET-AS remained in the hospital for 3 ~ 19 days.

CONCLUSIONS

these preliminary results suggest that ET-AS regimens are a safe and effective therapy for severe P. falciparum malaria and can benefit patients in clinical settings.

摘要

背景

尽管疟疾管理有所改善,但恶性疟原虫引起的严重疟疾死亡率仍然很高。

病例介绍

本病例系列旨在描述交换输血联合青蒿琥酯(ET-AS)方案治疗严重恶性疟的疗效和安全性。纳入 8 例诊断为严重恶性疟的患者。所有患者均采用 COBE Spectra 系统进行 ET。目标换血后血细胞比容为 30%。取出并替换一半估计的血容量使用新鲜冷冻血浆。该方案耐受良好,无并发症。寄生虫清除时间为 1 ~ 5 天。5 例脑型疟疾患者在 3 天内意识完全恢复,而 2 例溶血性疟疾患者在第 2 天好转。肝功能在 1 ~ 6 天内改善,1 例和 6 例患者的肾功能分别在第 18 天和第 19 天改善。重症监护病房的住院时间为 2 ~ 10 天,所有接受 ET-AS 治疗的患者均在医院住院 3 ~ 19 天。

结论

这些初步结果表明,ET-AS 方案是治疗严重恶性疟的一种安全有效的治疗方法,可使临床患者受益。

相似文献

3
UK malaria treatment guidelines 2016.
J Infect. 2016 Jun;72(6):635-649. doi: 10.1016/j.jinf.2016.02.001. Epub 2016 Feb 12.
7
Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria.
Clin Infect Dis. 2013 Mar;56(5):e48-58. doi: 10.1093/cid/cis958. Epub 2012 Nov 21.
8
Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.
Cochrane Database Syst Rev. 2019 Jan 8;1(1):CD006404. doi: 10.1002/14651858.CD006404.pub3.

本文引用的文献

3
Experimental malaria-associated acute kidney injury is independent of parasite sequestration and resolves upon antimalarial treatment.
Front Cell Infect Microbiol. 2022 Aug 8;12:915792. doi: 10.3389/fcimb.2022.915792. eCollection 2022.
4
Optimizing the Intensive Care Treatment of Severe and Complicated Malaria in Nonimmune Patients.
J Trop Med. 2020 Nov 21;2020:1628270. doi: 10.1155/2020/1628270. eCollection 2020.
6
Decreased Mortality of Malaria in Anemic Prisoners of War?
Am J Trop Med Hyg. 2020 Dec;103(6):2171-2173. doi: 10.4269/ajtmh.20-0791. Epub 2020 Sep 3.
7
Successful treatment of plasma exchange-refractory thrombotic thrombocytopenic purpura with rituximab: A case report.
World J Clin Cases. 2020 Jun 26;8(12):2617-2622. doi: 10.12998/wjcc.v8.i12.2617.
9
Manual exchange transfusion for severe imported falciparum malaria: a retrospective study.
Malar J. 2018 Jan 16;17(1):32. doi: 10.1186/s12936-018-2174-z.
10
Challenges to replace ACT as first-line drug.
Malar J. 2017 Jul 24;16(1):296. doi: 10.1186/s12936-017-1942-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验